Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 423 recruiting now early-phase tilt #1 of 28,707 conditions

Breast Cancer: early-phase trial registry

423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1 of 28,707 conditions by registered trial count.

1,251 US clinical trials · 423 currently recruiting · #1 of 28,707 conditions by registered trial count

Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.

Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.

Enrollment posture brief

Registry condition breast-cancer

OPEN 423 | RECR 34% | LATE 120 | EARLY 491 | RANK #1 | SPON 98

Nearest open-share peer: Refractory Multiple Myeloma (34% recruiting · 68 trials)

Prostate Cancer36.7%Depression35.7%Breast Cancer (this)34%Obesity28.9%Healthy20.5%
Open-enrollment share among volume-matched conditions near Breast Cancer

Breast Cancer lists 423 open slots (34% of 1,251 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Breast Cancer is recruiting below its size-band peers.

    423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Breast Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.

  3. Typical Breast Cancer enrolment sits around 90 participants.

    Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.

  4. Breast Cancer research is mostly interventional.

    1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1235Phase 2256Phase 3100Phase 420

Phase Distribution

PhaseTrial count
Phase 1 235
Phase 2 256
Phase 3 100
Phase 4 20

Named interventions

Most-linked intervention names on Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Fulvestrant Drug
33 trials
Paclitaxel Drug
32 trials
Trastuzumab Drug
26 trials
Letrozole Drug
24 trials
Pembrolizumab Drug
23 trials
Cyclophosphamide Drug
21 trials
Capecitabine Drug
20 trials
Abemaciclib Drug
19 trials

US sites by state

Facility locations filed on Breast Cancer trials. A trial with sites in several states counts in each.

California 298 trials
New York 270 trials
Texas 210 trials
Florida 206 trials
Massachusetts 184 trials
North Carolina 126 trials
Illinois 123 trials
Pennsylvania 122 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Breast Cancer page

1,251 registered trials, 423 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Cancer condition card totals 1,251 registered trials; most-linked intervention Fulvestrant; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.